ALKS — Alkermes plc
$47.03
+$0.05 (+0.11%)
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders.
Market Cap
$7.90B
Forward P/E
34.8x
52-Week Range
N/A
ALKS Price History
Revenue vs. Net Income
$1.5B
Revenue · FY2025
Annual. Net margin is shown under each year.
Free Cash Flow
$480M
FCF · FY2025
Annual. FCF margin is shown under each year.
Return on Capital Employed (ROCE)
15.6%
ROCE · FY2025
Annual. Green above 0%, red below. Dashed line marks the 15% compounder threshold.
Total Assets vs. Total Liabilities
3.7x
Assets ÷ liabilities · FY2025
Annual. What the company owns against what it owes. Assets ÷ liabilities is shown under each year.
CapEx as % of Revenue
2.7%
CapEx · FY2025
Annual. Green at or under the 5% maximum target, red above it.
Shares Outstanding
-0.3%
Net buyback · FY2025
Annual diluted shares. Under each year: the change on the previous year (green = buyback, amber = dilution).
